| 标题 |
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal for ImmunoTherapy of Cancer 作者:Howard West; Mark L. McCleland; Federico Cappuzzo; Martin Reck; Tony Mok; et al 出版日期:2022-02-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)